Medical World News

[Preciouslife1]

Bavi definitely works. Non I-O combination footprints are similar to those of anti-PDs. But, anti-PS, Bavi, in combination with anti-PDs or anti-CTLA-4, yield 200% to 300% higher response rates (RR). And this is what the coming NCCN immunotherapy combination clinical trials should start to demonstrate.

Through Bavi immunotherapy combinations, 30% response rates (RR) should move into the realm of 60% RR up to 90% RR.

The following recent results points to that high level of immuno-combination efficacy.

“...phosphatidylserine (PS)-targeting antibodies similar to bavituximab are able to enhance the anti-tumor activity of multiple checkpoint targeting agents including anti-PD-1 and anti-LAG3 therapies in a model of triple negative breast cancer (TNBC). Data showed that eight of the ten (80%) animals receiving the preclinical bavituximab equivalent (ch1N11) combined with anti-PD-1 and anti-LAG3 therapies ("Triple Combination") experienced complete tumor regressions, whereas there were no animals (0/10) in the anti-PD-1 and anti-LAG3 combination treatment arm that had a complete regression.

Additional data demonstrated that the Triple Combination featuring ch1N11 led to a 99% reduction in total tumor volume at the interim analysis point (Day 25) across all animals as compared to the control arm. In addition, the Triple Combination showed a statistically significant increase in tumor growth inhibition (TGI) as compared to the anti-PD-1 and anti-LAG3 combination treatment (99% vs. 62%; p < 0.05). Peregrine's Michael J. Gray, Ph.D., the study's lead scientist, presented the study findings at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference September 25-28, 2016, in New York City.”

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=991044